STAT+: Drug-testing lab that has sparked controversy sues group that develops drug standards over criticism
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Valisure filed a lawsuit in a U.S. court accusing U.S. Pharmacopeia of making "false and misleading" statements about the lab's drug-testing methods in a 2023 white paper.
- U.S. Pharmacopeia allegedly claimed Valisure uses "unvalidated methods" that yield "misleading results" and create "unnecessary concern" about medicine safety.
- Valisure previously clashed with regulators after detecting impurities in widely used medicines, according to the article.
- Valisure alleges USP's white paper was designed to cast the lab's testing as unreliable while portraying USP's own methods as "inherently and universally safe."
- Valisure further alleges USP acted to protect a medicine-standards system that "financially benefits" USP itself.
- U.S. Pharmacopeia operates as an independent organization that develops quality standards for medicines.
Why it matters: The case puts a public spotlight on the relationship between independent drug-testing labs and the body that writes U.S. medicine quality standards. Valisure's allegation that USP's critique was shaped to protect a system that "financially benefits" USP itself frames the fight as more than a technical disagreement over methods — it targets who has the standing to challenge drug safety in the first place.
Ask SkimNews
